Triclabendazole
Egaten is a prescription medication containing triclabendazole, an anthelmintic drug that treats parasitic infections by inhibiting certain liver enzymes. It is available as 250mg oral tablets manufactured by Novartis Pharmaceuticals Corporation, approved in 2019. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Egaten is a prescription medication containing triclabendazole, an anthelmintic drug that treats parasitic infections by inhibiting certain liver enzymes. It is available as 250mg oral tablets manufactured by Novartis Pharmaceuticals Corporation, approved in 2019. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Triclabendazole",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Triclabendazole — ANDA 208711 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208711"
}
]
|
| identifier | ANDA208711 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-manufacturers",
"drug-safety",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Triclabendazole |
